NCT05803759

The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment

The Effects of Dietary Supplementation Allicor on the Effectiveness of Treatment of Patients After Coronary Arteria Revascularization

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Institute for Atherosclerosis Research, Russia · Academic / Other
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Coronary revascularization interventions such as coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) are the standard of surgical treatment of patients with myocardial ischemia. However, up to 30% of patients experience complications of varying degrees within 12 months after the revascularization, or need for second intervention. Thus, it is necessary to search for additional approaches to the postoperative treatment of patients in order to improve the long-term results of revascularization treatment. Substances of natural origin with an anti-atherosclerotic effect have a good potential. These substances, as dietary supplements, can be taken by patients for a long time in conjunction with other prescribed medicines and treatments. Another valuable direction of investigations is the search for predictors of long-term cardiovascular complications after revascularization, which can be markers of inflammation and heteroplasmy levels of the patient's mitochondrial genome. The purpose of this study is to determine whether the intake of dietary supplement Allicor at a daily dose of 300 mg affects the frequency of long-term postoperative cardiovascular complications and re-intervention in patients after revascularization operations on the coronary arteries. The second goal is assessing the relationship between the grade monocytes inflammatory response and the level of heteroplasmy of the mitochondrial genome of blood leukocytes with the frequency of cardiovascular complications and re-interventions.

Conditions

• Myocardial Ischemia
• Coronary Artery Bypass Grafting
• Coronary Arteriosclerosis
• Percutaneous Coronary Revascularization

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Allicor	Each capsule contains 150 mg dried garlic powder
DRUG	Placebo	Capsules manufactured to mimic Allicor 150 mg capsules

Timeline

• Start date: 2023-04-10
• Primary completion: 2024-03-31
• Completion: 2025-03-31
• First posted: 2023-04-07
• Last updated: 2023-04-19

Locations

1 site across 1 country: Russia